Clinical trial registry record

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 24, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07215390
Last registry update
June 24, 2026
Status
Recruiting
Phase
Phase 2
Sponsor
Apellis Pharmaceuticals, Inc.
Enrollment
240
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
240
Population
ALL · 60 Years
Duration
2025-06-23 to 2027-11-01
Intervention
APL-3007, pegcetacoplan (APL-2); Placebo, Syfovre
Comparator
Group 3 (placebo)
Outcomes measured
Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the stu…; CFB in the area of AI-based OCT assessment of photoreceptor degeneration in the study eye — At month 12; Safety & tolerability based on adverse event (AE) reporting — At month 12; Safety as assessed by Best Corrected Visual Acuity (BCVA) — At Month 12; Change from baseline in Serum C3 level — At Month 12; CFB in RPE lesion area as assessed by FAF in the study eye — At month 12; CFB in the junctional zone, central 2o and 6o MP number of scotomatous points in the study eye — At month 12; CFB in the junctional zone, central 2o and 6o MP mean sensitivities in the study eye — At month 12; CFB in normal luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold Platform — At m…; CFB in low luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold platform — At mont…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON